In the News AACR 2026: ORGANOPlus Presents Preclinical Data on Microbiome-Derived Anticancer Candidate ‘OP820’ Apr 23, 2026 ORGANOPlus presented preclinical data on its microbiome-derived anticancer candidate ‘OP820’ at AACR 2026 in San Diego. The study demonstrated the anti-inflammatory and anticancer effects of Bifidobacterium adolescentis OP820, identified through the VILLIORGAN™ platform, which replicates the human intestinal microenvironment. These findings underscore ORGANOPlus’ platform capability to both discover and validate clinically relevant candidates in human-relevant systems. PreviousORGANOPlus Participates in Inha University Hospital Open Lab “Connect Day” Networking ForumNextAACR 2026 Highlights the Shift Toward Human-Relevant Platforms in Cancer Research Back to list
